---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037590"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:52:42.175602+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q2 net loss $157.9M; acoramidis Phase 3 ATTR-CM meets primary endpoint, NDA planned by end 2023

## Summary
- Phase 3 ATTRibute-CM of acoramids achieved highly significant primary endpoint, Win Ratio 1.8 (p<0.0001); NDA filing planned by end 2023.
- Revenue $1.6M in Q2 vs $73.7M prior year due to $70.2M one-time license in 2022; net loss $157.9M.
- Cash & equivalents $353.2M; mgmt expects $300-350M to support acoramidis launch.
- Announced positive infigratinib Phase 2 results in achondroplasia; mean AHV +3.38 cm/year.
- BBP-418 Phase 3 FORTIFY trial dosed first patient; FDA discussion supports accelerated approval potential.

## SEC filing metadata
- accession: 0000950170-23-037590
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017023037590/0000950170-23-037590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017023037590/bbio-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037590
- JSON: https://secwatch.observer/filing/0000950170-23-037590.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037590.txt

## Key facts
- Earnings Releases
  BridgeBio Pharma, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000095017023037590/0000950170-23-037590-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.